The European Alliance of Associations for Rheumatology (EULAR) has updated its recommendations for the management of systemic lupus erythematosus (SLE) based on emerging new evidence. For the 2023 ...

Aurinia welcomes the 2023 updated recommendations from EULAR for the management of systemic lupus erythematosus based on emerging new evidence, including a new treatment paradigm for lupus nephritis.

Key takeaways: EULAR has released new recommendations for non-pharmacologic management of lupus and systemic sclerosis. The new guideline includes recommendations encouraging physical exercise for ...

EULAR's Integrated Strategy for Systemic Lupus Erythematosus and Systemic Sclerosis Management A multidisciplinary task force of patient research partners, nurses, and health care professionals ...

Meeting Coverage > EULAR TYK2 Inhibitor Shows Promise in Lupus — Latest indication for deucravacitinib seen as approvable for multiple rheumatologic conditions by John Gever, Contributing Writer ...

Researchers conducted a literature review of systemic lupus erythematosus (SLE) studies and are calling for an update of the European League Against Rheumatism (EULAR) recommendations for the ...

HSS Study at EULAR 2025 Congress Uses an AI Model to Predict Readmissions of Pregnant Women with Lupus Based on Social Determinants of Health Hospital for Special Surgery (HSS) presented a ...

EULAR Past-President Professor Johannes W. Bijlsma says, "This gives a first clinical picture of the course of COVID-19 in SLE patients treated with HCQ.

The recommendations advise on managing cardiovascular health in patients with gout, vasculitis, systemic sclerosis, myositis, Sjögren syndrome, lupus, antiphospholipid syndrome, and other diseases.

All patients with lupus should receive hydroxychloroquine and, during chronic maintenance treatment, glucocorticoids should be minimized and withdrawn when possible, according to a 2019 update to ...

TORONTO, June 10, 2020 (GLOBE NEWSWIRE) -- Eli Lilly and Company presented new data for OLUMIANT® (baricitinib) at the virtual European Congress of Rheumatology (EULAR 2020).